Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs

PRECIGEN, INC.

Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.
Vesting in two 50% installments upon: (1) FDA submission of BLA for PRGN-2012, (2) FDA approval of BLA, both by Dec 31, 2026.
PSUs forfeited if milestones not achieved by end of Performance Period; vesting accelerated upon change in control in certain cases.
Pro-rata vesting applies on termination without cause or for good reason; full forfeiture on other termination events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.